Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment ...

Goldman Sachs also reaffirmed its Buy rating on VERA, arguing that the selloff is an overreaction as Otsuka’s (OTCPK:OTSKY) disclosure more or less aligned with future milestones in the IgAN space.

Goldman Sachs notes that Vera Therapeutics (VERA) shares are down 18% and underperforming the biotech group today following earnings results from Otsuka that included a comment on potential at ...